Chemed vs Option Care Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chemed Corp (CHE)

Q3 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

August 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

Latest24 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

Option Care Health Inc (OPCH)

Q3 202614 Jul – 7 Oct 2026

▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.
This is the single biggest new event and the main reason OPCH is moving now.
Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.
It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.
Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.
It shows the underlying business was still growing before the buyout, a real support for the stock.
Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.
It is the main counterweight explaining the weak standalone backdrop behind the buyout.

August 202614 Jul – 7 Oct 2026

▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.
This is the single biggest new event and the main reason OPCH is moving now.
Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.
It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.
Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.
It shows the underlying business was still growing before the buyout, a real support for the stock.
Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.
It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Latest14 Jul – 7 Oct 2026

▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.
This is the single biggest new event and the main reason OPCH is moving now.
Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.
It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.
Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.
It shows the underlying business was still growing before the buyout, a real support for the stock.
Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.
It is the main counterweight explaining the weak standalone backdrop behind the buyout.